FR2432525B1 - - Google Patents

Info

Publication number
FR2432525B1
FR2432525B1 FR7919890A FR7919890A FR2432525B1 FR 2432525 B1 FR2432525 B1 FR 2432525B1 FR 7919890 A FR7919890 A FR 7919890A FR 7919890 A FR7919890 A FR 7919890A FR 2432525 B1 FR2432525 B1 FR 2432525B1
Authority
FR
France
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
FR7919890A
Other languages
French (fr)
Other versions
FR2432525A1 (fr
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
INST INT PATHOLOGIE CELLULAIRE
Original Assignee
INST INT PATHOLOGIE CELLULAIRE
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by INST INT PATHOLOGIE CELLULAIRE filed Critical INST INT PATHOLOGIE CELLULAIRE
Publication of FR2432525A1 publication Critical patent/FR2432525A1/fr
Application granted granted Critical
Publication of FR2432525B1 publication Critical patent/FR2432525B1/fr
Granted legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/20—Carbocyclic rings
    • C07H15/24—Condensed ring systems having three or more rings
    • C07H15/252—Naphthacene radicals, e.g. daunomycins, adriamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
FR7919890A 1978-08-03 1979-08-02 Nouveaux derives de la doxorubicine, leur preparation et les compositions qui les contiennent Granted FR2432525A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
BE869485 1978-08-03

Publications (2)

Publication Number Publication Date
FR2432525A1 FR2432525A1 (fr) 1980-02-29
FR2432525B1 true FR2432525B1 (enExample) 1983-12-02

Family

ID=3861689

Family Applications (1)

Application Number Title Priority Date Filing Date
FR7919890A Granted FR2432525A1 (fr) 1978-08-03 1979-08-02 Nouveaux derives de la doxorubicine, leur preparation et les compositions qui les contiennent

Country Status (6)

Country Link
US (1) US4296105A (enExample)
JP (1) JPS5522697A (enExample)
CA (1) CA1115694A (enExample)
FR (1) FR2432525A1 (enExample)
GB (1) GB2027024B (enExample)
NL (1) NL191150C (enExample)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5124317A (en) 1985-08-02 1992-06-23 Farmitalia Carlo Erba S.P.A. Injectable ready-to-use solutions containing an antitumor anthracycline glycoside
US5124318A (en) * 1985-08-02 1992-06-23 Farmitalia Carlo Erba S.R.L. Injectable ready-to-use solutions containing an antitumor anthracycline glycoside
US5977082A (en) * 1985-08-02 1999-11-02 Pharmacia & Upjohn Company Injectable ready-to-use solutions containing an antitumor anthracycline glycoside
US6143864A (en) * 1994-06-28 2000-11-07 Merck & Co., Inc. Peptides
US5866679A (en) * 1994-06-28 1999-02-02 Merck & Co., Inc. Peptides
US5599686A (en) * 1994-06-28 1997-02-04 Merck & Co., Inc. Peptides
BE1008581A3 (fr) * 1994-08-19 1996-06-04 Wallone Region Prodrogues, composition pharmaceutique les comprenant et leur utilisation.
WO1996005863A1 (fr) * 1994-08-19 1996-02-29 La Region Wallonne Composes, composition pharmaceutique et dispositif de diagnostic les comprenant et leur utilisation
JP2543434Y2 (ja) * 1996-04-15 1997-08-06 マツダ株式会社 エンジンの排気管構造
US5998362A (en) * 1996-09-12 1999-12-07 Merck & Co., Inc. Conjugates useful in the treatment of prostate cancer
US5948750A (en) * 1996-10-30 1999-09-07 Merck & Co., Inc. Conjugates useful in the treatment of prostate cancer
US6391305B1 (en) 1997-09-10 2002-05-21 Merck & Co., Inc. Conjugates useful in the treatment of prostate cancer
TR200002260T2 (tr) * 1997-12-02 2000-12-21 Merck & Co., Inc. Prostat kanserinin tedavisinde yararlı konjugatlar
ZA9810974B (en) * 1997-12-02 1999-06-03 Merck & Co Inc Conjugates useful in the treatment of prostate cancer
US20040081659A1 (en) * 1997-12-02 2004-04-29 Merck & Co., Inc. Conjugates useful in the treatment of prostate cancer
US6174858B1 (en) 1998-11-17 2001-01-16 Merck & Co., Inc. Conjugates useful in the treatment of prostate cancer
US7425541B2 (en) * 1998-12-11 2008-09-16 Medarex, Inc. Enzyme-cleavable prodrug compounds
EP1225918A2 (en) 1999-10-19 2002-07-31 Merck & Co., Inc. Conjugates useful in the treatment of prostate cancer
CA2387901A1 (en) 1999-10-27 2001-05-03 Merck & Co., Inc. Salt form of a conjugate useful in the treatment of prostate cancer
WO2001036007A2 (en) * 1999-11-12 2001-05-25 Angiotech Pharmaceuticals, Inc. Compositions of a combination of radioactive therapy and cell-cycle inhibitors
AU2001266853B2 (en) * 2000-06-14 2005-02-17 Medarex, Inc. Prodrug compounds with an oligopeptide having an isoleucine residue
US7402556B2 (en) * 2000-08-24 2008-07-22 Medarex, Inc. Prodrugs activated by plasmin and their use in cancer chemotherapy
US20030232760A1 (en) * 2001-09-21 2003-12-18 Merck & Co., Inc. Conjugates useful in the treatment of prostate cancer
US20030216758A1 (en) * 2001-12-28 2003-11-20 Angiotech Pharmaceuticals, Inc. Coated surgical patches
KR20100110378A (ko) 2002-05-24 2010-10-12 안지오테크 인터내셔날 아게 의료용 임플란트를 피복하기 위한 조성물 및 방법
US8313760B2 (en) 2002-05-24 2012-11-20 Angiotech International Ag Compositions and methods for coating medical implants
US20040146546A1 (en) 2002-09-26 2004-07-29 Angiotech Pharmaceuticals, Inc. Perivascular wraps
ATE457716T1 (de) 2002-12-30 2010-03-15 Angiotech Int Ag Wirkstofffreisetzung von schnell gelierender polymerzusammensetzung
EP1687041A2 (en) * 2003-11-20 2006-08-09 Angiotech International AG Soft tissue implants and anti-scarring agents
EP1718145A4 (en) 2004-02-02 2012-03-07 Biosight Ltd CONJUGATES FOR CANCER THERAPY AND DIAGNOSIS
AU2005100176A4 (en) * 2005-03-01 2005-04-07 Gym Tv Pty Ltd Garbage bin clip
US9789209B2 (en) 2013-03-14 2017-10-17 The Regents Of The University Of California, Berke Activatable membrane-interacting peptides and methods of use
JP7149183B2 (ja) 2015-12-03 2022-10-06 バイオサイト リミテッド 癌治療のためのシタラビンコンジュゲート
US12071450B2 (en) 2015-12-03 2024-08-27 Biosight Ltd. Salts of conjugates for cancer therapy
IL259569B2 (en) 2015-12-03 2024-03-01 Biosight Ltd Salts of cytarabine-amino acids conjugates
US12064445B2 (en) 2015-12-03 2024-08-20 Biosight Ltd. Cytarabine conjugates for cancer therapy
WO2017094011A1 (en) 2015-12-03 2017-06-08 Biosight Ltd. Salts of conjugates for cancer therapy

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1578734A (enExample) * 1967-11-28 1969-08-22
FR7164M (enExample) * 1968-02-22 1969-08-04
FI51808C (fi) * 1968-07-15 1977-04-12 Rhone Poulenc Sa Menetelmä uusien kasvainten naftaseenijohdannaisten valmistamiseksi.
GB1500421A (en) * 1975-01-22 1978-02-08 Farmaceutici Italia Optically active anthracyclinones
US4012448A (en) * 1976-01-15 1977-03-15 Stanford Research Institute Synthesis of adriamycin and 7,9-epiadriamycin
FR2430425A1 (fr) * 1978-07-07 1980-02-01 Rhone Poulenc Ind Nouveaux derives de la daunorubicine, leur preparation et les compositions pharmaceutiques qui les contiennent

Also Published As

Publication number Publication date
JPS5522697A (en) 1980-02-18
GB2027024B (en) 1983-04-27
JPS6259715B2 (enExample) 1987-12-12
NL191150C (nl) 1995-02-16
US4296105A (en) 1981-10-20
FR2432525A1 (fr) 1980-02-29
NL191150B (nl) 1994-09-16
NL7905953A (nl) 1980-02-05
CA1115694A (en) 1982-01-05
GB2027024A (en) 1980-02-13

Similar Documents

Publication Publication Date Title
AU3898778A (enExample)
AU3803078A (enExample)
AU73950S (enExample)
AU3892778A (enExample)
BG26008A1 (enExample)
BG26006A1 (enExample)
BE871570A (enExample)
BG25806A1 (enExample)
BG25814A2 (enExample)
BG25816A1 (enExample)
BG25818A1 (enExample)
BG25835A1 (enExample)
BG25836A1 (enExample)
BG25842A1 (enExample)
BG25843A1 (enExample)
BG25849A1 (enExample)
BG25854A1 (enExample)
BG25857A1 (enExample)
BG25858A1 (enExample)
BG26012A1 (enExample)
BG25872A1 (enExample)
BG25874A1 (enExample)
BG25875A1 (enExample)
BG25879A1 (enExample)
BG25889A1 (enExample)

Legal Events

Date Code Title Description
ST Notification of lapse